Entering text into the input field will update the search result below

Global Blood Therapeutics, Inc. (GBT) CEO Dr. Ted Love on Q1 2021 Results - Earnings Call Transcript

May 05, 2021 10:09 PM ETPfizer Inc. (PFE)
SA Transcripts profile picture
SA Transcripts

Global Blood Therapeutics, Inc. (GBT) Q1 2021 Results Conference Call May 5, 2021 4:30 PM ET

Company Participants

Steven Immergut - SVP, Head of Corporate Communications and IR

Dr. Ted Love - President and Chief Executive Officer

Jeff Farrow - Chief Financial Officer

David Johnson - Chief Commercial Officer

Dr. Kim Smith Whitley - EVP and Head of R&D

Conference Call Participants

Alethia Young - Cantor Fitzgerald

Akash Tewari - Wolfe Research

Lyla Youssef - Cowen & Company

Xinyue Lu - RBC Capital Markets

Jason Gerberry - Bank of America

Andreas Argyrides - Wedbush Securities

Danielle Brill - Raymond James

Yanan Zhu - Wells Fargo

Paul Choi - Goldman Sachs

Yatin Suneja - Guggenheim Partners

Matthew Harrison - Morgan Stanley

Joon So Lee - Truist Securities

Samantha Corwin - William Blair


Greetings, and welcome to the Global Blood Therapeutics Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow prepared remarks. [Operator instructions] As a reminder, this conference is being recorded.

I would now like to turn the call over to Steven Immergut. Please go ahead.

Steven Immergut

Thank you, and welcome to GBT's conference call to discuss the Company's financial results for the first quarter of 2021 and to provide a business update. I'm Steven Immergut, Head of Communications and Investor Relations. Joining me on the call are Dr. Ted Love, our President and CEO, who will provide an update on our progress in the first quarter; Jeff Farrow, our Chief Financial Officer, we'll review our financial results; David Johnson, or DJ, our Chief Commercial Officer, will give an update on the Oxbryta launch. Ted will then introduce Dr. Kim Smith Whitley, who joined GBT this week as Executive Vice President and Head of R&D. Kim will provide a view on the current environment for sickle cell patient care. Ted will then close with an update on our pipeline

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.